Research programme: cancer therapeutics - Abiogen/University of Texas

Drug Profile

Research programme: cancer therapeutics - Abiogen/University of Texas

Alternative Names: cUV3; Moab-Anti-CD 54; Platinum-Cholic Acid Complex; PT-C

Latest Information Update: 21 Aug 2010

Price : $50

At a glance

  • Originator Abiogen Pharma; University of Texas Southwestern Medical Center
  • Class Cholic acids; Monoclonal antibodies; Platinum complexes
  • Mechanism of Action CD antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Malignant melanoma; Multiple myeloma
  • Discontinued Cancer

Most Recent Events

  • 30 Jul 2010 Preclinical development of the anti-CD54 monoclonal antibody cUV3 is ongoing in Italy for Malignant ocular melanoma and Multiple myeloma
  • 18 Mar 2008 Preclinical trials in Malignant ocular melanoma in Italy (Parenteral)
  • 10 Jun 2004 Preclinical trials in Multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top